| CPC G16H 20/13 (2018.01) [G07C 9/00182 (2013.01); G07C 9/00896 (2013.01)] | 32 Claims |
|
1. A computer-assisted method for autonomously tracking and administering medicaments by a tracking system, the method comprising:
receiving, from a processor of a user device, a request for administering a medicament to a patient, the request comprising a scanned identifier associated with the patient and a labeled dual chamber device (DCD), wherein the labeled DCD comprises a first chamber having one or more lyophilized components, a second chamber having a reconstitution buffer therein, and a locking mechanism comprising a transmitter communicatively coupled to the processor of the user device for controlling access to at least one of the first chamber and the second chamber;
querying, by a tracking engine comprising at least one processor executing one or more computer readable instructions, an administration database based on the scanned identifier to find a notarized ledger associated with the labeled DCD wherein the notarized ledger comprises at least one notarized ledger entry and is stored in the administration database;
retrieving, by the tracking engine when the notarized ledger is found, a notarized ledger entry comprising a first distributed ledger transaction identifying: i) the one or more lyophilized components within one or more vials of the labeled DCD, ii) a patient-specific therapeutic, and iii) a digital token associated with an owner of the labeled DCD;
receiving from an authentication engine comprising at least one processor executing one or more computer readable instructions, at least one authorization code associated with the owner of the labeled DCD for authenticating the owner of the labeled DCD by at least one authentication technique using the digital token;
validating the patient-specific therapeutic at the authentication engine by verifying the patient as the owner of the labeled DCD by transmitting the at least one authorization code to the user device and receiving the at least one authorization code from the user device identifying the owner of the labeled DCD;
creating, by the tracking engine in response to the validation of the patient-specific therapeutic, a second distributed ledger transaction based on the first distributed ledger transaction and including an indicator identifying the one or more lyophilized components as being authorized for administration to the patient;
authorizing, by the tracking engine in response to the creation of the second distributed ledger transaction, autonomous access to the one or more lyophilized components in the labeled DCD by transmitting the indicator to the user device; and
transitioning, by the user device in response to receiving the indicator, the locking mechanism from a locked state to an unlocked state with respect to at least one of the first chamber and the second chamber such that the patient-specific therapeutic can be administered to the patient.
|